The aims of this study were to examine, in vivo, the effects of GH treatment on myocardial energy metabolism, function, morphology, and neurohormonal status in rats during the early postinfarct remodeling phase.
C ONGESTIVE HEART FAILURE (CHF) remains a syndrome associated with high mortality in spite of recent advances in pharmacological treatment. Therefore, the search for new therapeutic approaches to improve both patient symptoms and survival continues. Accumulating experimental and clinical evidence suggests that GH may have beneficial effects in the treatment of CHF (1, 2) , although other studies reported different results (3, 4) . Apart from the observation that GH increases amino acid transport in perfused rat hearts (5), little is known about the specific effects of GH on myocardial metabolism, in general, and on energy metabolism, in particular. 31 P Magnetic resonance spectroscopy ( 31 P MRS) has been proven to be a powerful tool in the studies of cardiac energy metabolism because it allows unique noninvasive and nondestructive investigation of the heart (6). The technique has been successfully used in vitro (7) and in vivo (8, 9) in different animal models, as well as in humans, for evaluation of cardiac energy metabolism during infarction (10) , cardiomyopathy (11) , and heart failure (12) .
Activation of regional sympathetic systems in the heart and in other organs is a known phenomenon in heart failure (13, 14) . Overwhelming evidence supports the concept that overactivation of this system significantly contributes to the progression of CHF (13, 15) . Furthermore, a marked activation of the sympathetic nervous system has also been reported in GH-deficient patients (16) . However, the relationship between the GH-insulin-like growth factor I (GH-IGF-I) axis and sympathetic system has not been fully clarified at the present time.
The aims of this study were: 1) to examine, in vivo, the effects of GH on myocardial energy status (using volumeselective 31 P MRS) and function (using echocardiography) in rats during early postinfarct remodeling phase; and 2) to evaluate the effect of GH treatment on myocardial and plasma catecholamines, myocardial ␤-adrenoreceptors, and plasma brain natriuretic peptide (BNP) content.
Materials and Methods

Animals and experimental myocardial infarction (MI)
The study protocol was approved by the Animal Ethics Committee of the Gothenburg University and was conducted in accordance with NIH guidelines for use of experimental animals. The induction of MI was performed on male Sprague Dawley rats (B & K Universal, Sollentuna, Sweden), weighing 200 -250 g, according to the previously described method (17).
3 days post infarct and 3 weeks later. The size of MI was estimated according to the score system (20) . Although the score system used for estimation of infarct size provides a reasonable estimate, the low number of animals may have been a limitation.
Only the rats with large infarcts and ejection fraction (EF) less than 45% were selected. Animals that did not shown signs of MI were defined as sham-operated (sham, n ϭ 8). Rats with MI were randomized into two groups [control group (MI, n ϭ 7) and GH group (MI ϩ GH, n ϭ 11)]. The MI ϩ GH group received recombinant human GH (rhGH) continuously (3 mg/kg⅐day for 3 weeks), delivered by implanted osmotic pumps (Alzet, 2ML4, Alza Corp., Palo Alto, CA), starting at 3 days post infarct. The control group (MI) received saline. Systolic blood pressure was measured by the indirect cuff-tail method (9) (RTBP Monitor, Harvard Apparatus, Inc., South Natik, MA).
In vivo 31 P MRS of the rat heart
Volume-selective, cardiac 31 P MRS experiments were performed on a 2.35 Tesla horizontal magnet with a 20-cm bore (BioSpec 24/30, Bruker Medical GmbH, Rheinstetten, Germany) according to the method previously described by our laboratory (9) . The myocardial PCr/ATP ratio was corrected for partial saturation and for blood contamination (6, 21) . After completion of the second 31 P MRS examination, the rats were killed by rapid excision of the heart.
Radioligand binding for ␤-adrenoceptor assessment
Cardiac tissue, without macroscopic adipose or connective tissue, was minced and homogenized in buffer consisting of 50 mm Tris HCl and 10 mm MgCl 2 . The protein content of homogenate was measured according to Lowry. ␤-adrenoceptors were determined by use of ( 125 I) iodocyanopindolol using standard binding assay.
Serum levels of rhGH and IGF-I
The serum concentration of IGF-I was determined by a hydrochloric acid-ethanol extraction RIA using human IGF-I for labeling (Nichols Institute Diagnostics, San Juan Capistrano, CA). The assay was performed according to the manufacturer's protocol. The levels of rhGH in the plasma from rats treated with rhGH were determined by a polyclonal antibody-based immunoradiometric assay (Pharmacia, Uppsala, Sweden).
Biochemical analysis of catecholamines in plasma and myocardium
Myocardial and plasma levels of catecholamines, noradrenaline (NA), adrenaline (A), and dopamine (DA) were measured by means of HPLC with electrochemical detection (Gynkotek HPLC, Germering bei Mü nchen, Germany) according to the standard techniques using a modified procedure (22) .
BNP
The blood sample was drawn from the right ventricle (RV) and was transferred to ice-cold tubes containing aprotinin (1000 kIU/ml) and Na 2 EDTA (1 mg/ml) and was centrifuged at 4 C. Plasma samples were stored at 20 C until assay. The plasma concentration of BNP was measured with 250 l plasma using RIA according to the manufacturer's protocol (Peninsula Laboratories, Inc., San Carlos, CA).
Hypophysectomy
To evaluate whether GH has a direct effect on myocardial bioenergetics, cardiac 31 P MRS was performed in hypophysectomized male Sprague Dawley rats (Mö llegård, Breeding Centre, Ltd., Ejby, Denmark). Two different groups of rats were used: hypophysectomized rats replaced only with hydrocortisone (0.25 mg/kg⅐day) and l-T 4 (20 g/ kg⅐day) (n ϭ 5); and hypophysectomized rats replaced with hydrocortisone, l-T 4 in the same doses, and GH (1 mg/kg⅐day) (n ϭ 6). Replacement with hydrocortisone and l-T 4 was started immediately after hypophysectomy, whereas GH was given during weeks 5-6 after hypophysectomy. Hydrocortisone and l-T 4 were delivered by implanted osmotic pumps, whereas GH was given by sc injection. 31 P MRS examination of the heart was performed 6 weeks after hypophysectomy.
Statistics
One-way ANOVA (of single measurements and change from baseline/3 days post infarct), followed by Fisher PLSD post hoc test, was applied to detect significant differences. Normal distribution of the data was assessed using a Kolmogorov-Smirnov test. When data were not normally distributed, a nonparametric test was applied. The value P Ͻ 0.05 was considered as statistically significant. All data are presented as mean Ϯ sem.
Results
Animals
Three days post infarct, rats with MI had significantly lower body weight, compared with sham rats (Table 1) . During the treatment period of 3 weeks, there was a significant increase in body weight in all experimental groups. All three groups have shown similar increase in body weight during the experimental time. However, body weight was signifi- cantly lower in MI rats, compared with the sham group, also at the end of the study. Treatment with rhGH did not result in further increase in body weight, compared with the controls. There was no significant difference in LV or RV weight after rhGH treatment, compared with the control group.
Echocardiography and hemodynamics
Three days after MI and before the initiation of the GH treatment, the GH and control groups were comparable, with regard to infarct size score (Table 1) , heart rate (HR), EF, and left ventricular dimensions (Tables 2 and 3 ). At the same time, fractional shortening (FS) was significantly lower, whereas left ventricular volumes in systole and diastole were significantly higher in the GH group. Rats with MI had significantly lower EF, FS, and higher LV volumes and dimensions, compared with sham rats, indicating early systolic dysfunction and rapid dilatation of infarcted LV.
After 3 weeks treatment with rhGH, EF and FS increased by 1.7 U (6.6%) and 3.8 U (26%), respectively, in the GH group. In the control group, EF and FS decreased by 4 U (12%) and 1.5 U (8%), respectively. The treatment with rhGH attenuated progression of pathologic LV remodeling, as evidenced by significantly lesser increase in LV volumes and dimensions. The treatment with GH did not affect HR, left ventricular diameter in diastole, stroke volume, stroke volume index, and left ventricular systolic wall stress.
The decceleration slope of the mitral E-wave was significantly higher in MI rats, compared with sham, at base line and was not affected 3 weeks later, after the treatment with GH. There was a tendency toward decreased E/A wave ratio in the GH-treated group. Systolic blood pressure was not different between the groups either 3 days or 3 weeks post infarct. Compared with base line, WS decreased only in the GH group, although this difference was not statistically significant.
Left ventricular energy status assessed by volume-selective 31 P MRS
The PCr/ATP ratio was not significantly different between control and rhGH groups at the base line (MI ϭ 1.45 Ϯ 0.07; MI ϩ GH ϭ 1.58 Ϯ 0.06; sham ϭ 2.42 Ϯ 0.3), whereas both groups had significantly lower PCr/ATP ratio, compared with the sham group (P Ͻ 0.0001) (Fig. 1, A and B) . After 3 weeks treatment with rhGH, the PCr/ATP ratio increased significantly, compared with the control group, and reached the same value as in the sham group, suggesting normalization of cardiac energy status (MI ϩ GH ϭ 2.42 Ϯ 0.05 vs. MI ϭ 1.69 Ϯ 0.09, P Ͻ 0.001; sham ϭ 2.34 Ϯ 0.08). In hypophysectomized rats without GH substitution, the PCr/ATP ratio was significantly decreased at 6 weeks after hypophysectomy, whereas 2 weeks of GH substitution normalized the PCr/ATP ratio (1.63 Ϯ 0.12 vs. 2.45 Ϯ 0.05; P Ͻ 0.0001) (Fig. 2) .
Serum IGF-I and rhGH levels
Serum IGF-I was significantly lower in MI rats, compared with sham rats. GH did not significantly increase serum-IGF-I. The levels of human GH were high in treated rats (Table 4) .
␤-adrenoceptors, plasma, and myocardial content of catecholamines
Three weeks after treatment with rhGH, the myocardial content of NA was 41% lower in the GH group, compared with the placebo group (Table 4 and Fig. 3A) . Myocardial DA was significantly lower in the GH group, compared with the sham group, whereas the difference was not significant, compared with controls. Neither myocardial nor plasma concentration of A was different between the groups. The rhGHtreated rats had significantly lower plasma NA levels, compared with the control group (Fig 3B) . There was no difference in plasma levels of DA and A and in myocardial content of ␤-adrenoceptors between the groups.
Plasma brain natriuretic factor
Plasma BNP levels were significantly lower in the rhGHtreated group, compared with the control group (Fig 4) . No difference was found between sham and rhGH-treated rats.
FIG. 1. A, Representative
31 P MR spectra from control (MI), rhGH-treated (MI ϩ rhGH), and sham rats at 3 weeks after induction of myocardial infarct of the anterolateral left ventricular wall. The spectra were obtained using the image selected in vivo spectroscopy localization method, with VOI ϭ 168 cm 3 , including whole LV. Note the difference in the PCr/ATP ratio, between control and rhGH-treated rats. PCr, Phosphocreatine; 2,3-DPG, diphos-phoglycerate; Pi, inorganic phosphate; PDE, phosphodiesters; MI, control rat with myocardial infarct; MI ϩ rhGH, rat with myocardial infarct treated with rhGH. B, Effect of 3 weeks treatment with GH on left ventricular energy status (PCr/ATP) in rats with postinfarct heart failure. The treatment was initiated early in the postinfarct phase (3 days post infarct) by continuous delivery of rhGH (3 mg/kg/ day). The PCr-to-ATP ratio was normalized in the rats on rhGH treatment. †, P Ͻ 0.0001 vs. Sham; #, P Ͻ 0.0001 vs. base line; *, P Ͻ 0.0001 vs. MI; ¤, P Ͻ 0.001 effect of treatment with rhGH (MI-rhGH) vs. control (MI).
Discussion
The most important findings of this study are: 1) early treatment with rhGH improved left ventricular energy status in the rats with postinfarct remodeling; 2) the myocardial (LV) and plasma levels of NA were significantly lower in rhGH-treated rats with large MI; and 3) treatment with rhGH preserved LV systolic function, attenuated LV remodeling, and normalized plasma BNP levels.
Effects of early treatment with rhGH on cardiac bioenergetics
Accumulating evidence suggests that the failing heart is an energy-depleted organ (23) . Our laboratory has previously reported that disturbances in myocardial energy metabolism ensue early in the postinfarct period (9) and that lowering of myocardial energy reserve correlates with parameters of LV systolic and diastolic dysfunction, as well as with LV wall stress (24) . Failing and hypertrophied myocardium is characterized by several consistent changes in the cellular energetic system, regardless of species (25, 26) . The PCr-to-ATP ratio is a commonly used index of cellular energy status, because it reflects the equations of cellular phosphorylation potential [a driving chemical force for energy-dependent intracellular events (12, 27) ].
It is well known that GH has profound influence on the regulation of carbohydrate, protein, and fatty acid metabolism. However, little is known about the specific metabolic effects of GH at the level of the heart and whether GH directly affects cellular energy metabolism. Initial experimental and clinical studies in which GH was used as treatment for heart failure suggested that GH might lower energetic demand of the failing heart by reducing LV wall stress and afterload. Other reports suggested that GH might positively affect the economy of energy utilization at cross-bridge reactions in the myocytes (28) . However, the hypothesis that GH could improve cardiac energy status was never tested adequately and directly in vivo. In this study, the effect of GH treatment on myocardial bioenergetics was assessed in vivo and noninvasively using volume-selective cardiac 31 P MRS. The study demonstrates that short-term treatment with rhGH in the early postinfarct phase normalizes the myocardial PCr/ATP ratio. Because the treatment with rhGH normalized the PCr/ ATP ratio without induction of either LV hypertrophy or significant change in WS, antiremodeling effect cannot entirely explain this result. It is more likely that the improvement in myocardial bioenergetics is largely independent of GH's antiremodeling effect. This hypothesis is supported by our observation that hypophysectomized rats without GH substitution have shown a decreased myocardial PCr/ATP ratio, which was normalized after 2 weeks of GH substitution. The underlying mechanism for this is unknown, but previous studies have shown that GH is involved in the regulation of cellular enzymes important for creatine synthesis (29) . Further experiments are needed to evaluate whether insufficient creatine production may be the reason for decreased PCr/ATP in GH-deficient rats. It has also been shown that IGF-I stimulates uptake of both creatine and inorganic phosphate by muscle cells under in vitro conditions (30, 31) . It is tempting to speculate that treatment with GH could increase uptake of creatine and Pi by local stimulation of IGF-I production. However, because the plasma levels of IGF-I were not different between rhGH-treated and control groups, and local levels of IGF-I were not measured, this assumption remains to be investigated in the future. Furthermore, it is also important to investigate whether GH directly affects these transport mechanisms mediated through GH receptors in the myocardium.
Effects of GH on left ventricular function and morphology
Previous studies have demonstrated beneficial effects of GH on systolic function in rats after experimental MI (1, 32) . In the present study, a moderate effect of rhGH on cardiac performance was observed, manifested as a preservation of function rather than improvement. This may be attributed to the fact that rhGH was added in the early post-MI phase rather than in a chronic setting, as previously reported (1). However, normalization of plasma BNP after rhGH treatment strongly suggests early beneficial effects of rhGH on hemodynamics after MI. To our knowledge, this is the first time that rhGH effects on BNP levels have been reported.
Treatment with rhGH attenuated pathologic remodeling of LV in the rats with MI. This is in accordance with previous studies (32) , although these findings are not always consistent (33, 34) . In the study by Shen et al. (34) , GH treatment did not affect cardiac function and remodeling either in normal or hypophysectomized female rats with MI. There are several possible reasons for the divergence in the results. In this study, male rats, instead of female, were used. Previous studies have clearly demonstrated that gender differences exist regarding response to the treatment with GH. Female rats have slower spontaneous growth rate and show a less pronounced response to the exogenously administered GH (35) . The reason for this is unknown, but multiple studies have indicated a lower number of GH receptors and higher concentration of GHbinding proteins as possible contributing factors (36) . Ad- ditionally, the use of one-time observations (34) may preclude detection of small, but significant, beneficial effects of GH treatment. Although attenuation of increase in LV volumes was only modest, this effect, together with no significant increase in the LV weight, suggests an antiremodeling effect of rhGH treatment. These findings prompt the tempting hypothesis that patients with postinfarct remodeling ,and possibly CHF, may benefit from the rhGH treatment without need for induction of LV hypertrophy, as previously proposed (2). This is an important issue because it is generally accepted that LV hypertrophy is an independent risk for mortality in the patients with CHF in progress.
Effects of GH on catecholamines and ␤-adrenoceptors
One rather unexpected result was that of markedly decreased myocardial content of NA in animals treated with rhGH. Not only myocardial content of NA but also plasma NA were significantly lower in rats receiving rhGH. The interaction between GH and sympathetic system is probably complex and is not completely understood at the present time. Previous clinical studies indicate that GH may have pronounced effects in the regulation of sympathetic function, which is based on the fact that patients with GH deficiency have markedly increased activation of the sympathetic nerve fibers firing in skeletal muscle (16) . Furthermore, GH treatment of patients with dilated cardiomyopathy results in attenuation of cardiac sympathetic activation under stress conditions (37) . Our findings are congruent with these observations. The marked lowering of myocardial catecholamine content, after rhGH treatment, suggests an important role of rhGH in regulation of the cardiac sympathetic system and catecholamines. The present study does not allow any conclusions regarding the mechanisms and pathophysiological importance for these findings, and further studies are necessary. However, it is unlikely that diminished stores of myocardial NA are a result of increased release and/or decreased uptake. This assumption is supported by the fact that neither HR nor myocardial content of ␤-adrenoceptors was different between the groups. It has been established that down-regulation of ␤-adrenoceptors is one consequence of cellular exposure to high NA levels (38) . In the early phase of heart failure, there is an organ-selective activation of the cardiac sympathetic system, and the catecholamine spillover from the heart is 3-4 times higher than normal (14) . If GH specifically increases release and/or decreases reuptake of NA, one would expect depletion of myocardial stores to be associated with increased plasma NA levels. Even if the long-term consequences of this effect are not known, lowering of tissue NA content in the early postinfarct phase, together with low plasma NA concentration, could have protective effects on damaged and remodeling myocardium. Experimental studies have shown that NA, in high concentration (similar to that known to occur in the neuromuscular synapses of failing myocardium), exerts direct pathological effects on cardiomyocytes. These effects include cell necrosis, stimulation of apoptosis, increase in interstitial fibrosis, arrhythmias, and others (39, 40) . Furthermore, increased adrenergic drive can decrease the contents of creatine and CK in the heart, indicating adverse effects on cellular energetic homeostasis (41) . While improving LV function by other mechanisms independent of the sympathetic system, addition of rhGH could, at the same time, protect myocardium from the side effects of sympathetic overactivation. This hypothesis, however, has to be taken with caution and proven in future experiments. One has to keep in mind that depletion of myocardial catecholamines is a consistent finding in patients with advanced heart failure. Exhaustion of catecholamine stores in cardiac neurons is proposed to be involved in mechanisms behind LV dysfunction.
In summary, 3 weeks of treatment with rhGH, in the early postinfarct phase, improved myocardial energy status, attenuated postinfarct pathologic remodeling of LV, and decreased myocardial and plasma catecholamine levels in rats with large MI. These effects were accompanied by preservation of left ventricle function and normalization of BNP levels in plasma. These findings provide novel evidence in favor of the concept that GH may have a place in the treatment of postinfarct remodeling.
